Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate présentera des données actualisées de son nouvel inhibiteur de la voie PAM DIACC3010 dans le cancer du sein métastatique ER+ HER2- à l’AACR 2023 DIACC3010 a une excellente activité...
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023
April 06, 2023 08:30 ET
|
DIACCURATE
Diaccurate Announces Updated Data on its Novel PAM Pathway Inhibitor DIACC3010 in Patients with ER+ HER2- Metastatic Breast Cancer to be Presented at AACR 2023 DIACC3010 displays broad efficacy in...
Sermonix to Present Poster Comparing Lasofoxifene and Fulvestrant Effect on Vaginal Health at International Society for the Study of Women's Sexual Health Annual Meeting 2023
February 08, 2023 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Feb. 08, 2023 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat metastatic breast...
Immutep Announces Successful Meeting with the FDA on Eftilagimod Alpha plus Chemotherapy for the Treatment of Metastatic Breast Cancer
December 23, 2022 08:00 ET
|
Immutep Limited
Agreement with FDA on Phase II/III trial design positions the Company to exploit eftilagimod alpha’s potential to address high unmet need for metastatic breast cancer patientsPatient population...
Sermonix Shares Two Recently Presented Posters Evaluating ESR1 Mutations in Circulating Tumor DNA From Patients With ER+/HER2- Metastatic Breast Cancer Who Were Treated With Lasofoxifene
December 19, 2022 09:00 ET
|
Sermonix Pharmaceuticals Inc.
Posters were presented Dec. 9 at the San Antonio Breast Cancer Symposium (SABCS)One abstract addressed patients who participated in the randomized Phase 2 ELAINE 1 study that assessed investigational...
Sermonix Shares Two Posters at SABCS 2022 on ER+/HER2- Metastatic Breast Cancer Patient Survey About Knowledge of NGS and ESR1 Mutations, Quality of Life Concerns
December 09, 2022 08:00 ET
|
Sermonix Pharmaceuticals Inc.
SAN ANTONIO, Dec. 09, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
Sermonix Pharmaceuticals Announces Poster Presentation on Phase 1 Ethnobridging Study of Lasofoxifene at the 12th AACR-JCA Joint Conference: Breakthroughs in Cancer Research — Translating Knowledge Into Practice
December 08, 2022 12:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Dec. 08, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Announces Four Abstracts Accepted for Presentation at 2022 San Antonio Breast Cancer Symposium
November 17, 2022 09:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative targeted therapeutics to specifically treat...
Sermonix Pharmaceuticals Shares Additional Findings From Its ELAINE 1 Clinical Study at the 4th Annual Congress of the International Society of Liquid Biopsy
October 21, 2022 10:00 ET
|
Sermonix Pharmaceuticals Inc.
COLUMBUS, Ohio, Oct. 21, 2022 (GLOBE NEWSWIRE) -- Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company developing innovative therapeutics to specifically treat ESR1-mutated...
Sermonix Pharmaceuticals Shares Details of First-Ever Known Durable Complete Clinical Response in a Metastatic ER+/HER2- Breast Cancer Patient With an ESR1 Mutation After Prior CDK4/6 Inhibitor Treatment Via Single-Agent Hormonally Based Regimen
September 14, 2022 11:22 ET
|
Sermonix Pharmaceuticals Inc.
Presentation delivered at the ninth-annual Metastatic Breast Cancer Research Conference in Park City, Utah Case was reported during Phase 2 study investigating efficacy of lasofoxifene, Sermonix’s...